-
公开(公告)号：US20130089595A1
公开(公告)日：2013-04-11
申请号：US13688116
申请日：2012-11-28
IPC分类号： A61K47/36
CPC分类号： A61K47/36 , A61K9/0014 , A61K9/06 , A61K31/07 , A61K31/12 , A61K31/519 , A61K31/568 , A61K38/2292 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.
摘要翻译： 本发明提供稳定的，自组装的，生物相容的和可生物降解的水凝胶制剂，其中可以并入一种或多种化合物，从而当水凝胶在体内降解时延迟释放或控制释放所掺入的化合物。
-
公开(公告)号：US20130273140A1
公开(公告)日：2013-10-17
申请号：US13915604
申请日：2013-06-11
IPC分类号： A61K47/26
CPC分类号： A61K47/36 , A61K9/0014 , A61K9/06 , A61K31/07 , A61K31/12 , A61K31/519 , A61K31/568 , A61K38/2292 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.
-
公开(公告)号：US08470370B2
公开(公告)日：2013-06-25
申请号：US13688116
申请日：2012-11-28
IPC分类号： A61K9/10 , A61K31/12 , A61K31/519 , A61K31/122 , A61K31/56 , A61K38/22 , A61K38/02 , A61P25/28 , A61P19/02
CPC分类号： A61K47/36 , A61K9/0014 , A61K9/06 , A61K31/07 , A61K31/12 , A61K31/519 , A61K31/568 , A61K38/2292 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.
摘要翻译： 本发明提供稳定的，自组装的，生物相容的和可生物降解的水凝胶制剂，其中可以并入一种或多种化合物，从而当水凝胶在体内降解时延迟释放或控制释放所掺入的化合物。
-
公开(公告)号：US20210220346A1
公开(公告)日：2021-07-22
申请号：US17055647
申请日：2019-05-15
发明人： Roger Crystal , Phil Skolnick , Edward T. Maggio
摘要： Formulations and methods for the preventative treatment of incidental opioid overdose comprising the intranasal (IN) administration of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.
-
公开(公告)号：US10046025B2
公开(公告)日：2018-08-14
申请号：US15264393
申请日：2016-09-13
发明人： Edward T. Maggio
摘要： The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a cyclic polypeptide.
-
公开(公告)号：US20180221489A1
公开(公告)日：2018-08-09
申请号：US15942110
申请日：2018-03-30
发明人： Edward T. Maggio
IPC分类号： A61K47/26 , A61K31/137 , A61K31/138
CPC分类号： A61K47/26 , A61K9/0043 , A61K9/0048 , A61K9/0056 , A61K9/006 , A61K9/2018 , A61K9/2095 , A61K31/137 , A61K31/138 , A61K31/4439 , A61K31/70
摘要： The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
-
公开(公告)号：US20170189472A1
公开(公告)日：2017-07-06
申请号：US15465406
申请日：2017-03-21
发明人： Edward T. Maggio
CPC分类号： A61K38/12 , A01N33/08 , A01N43/16 , A61K9/0043 , A61K9/0048 , A61K9/08 , A61K31/4439 , A61K31/70 , A61K38/29 , A61K47/183 , A61K47/26 , Y02A50/473
摘要： Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 in preventing growth of specified bacteria and fungi.
-
公开(公告)号：US09446134B2
公开(公告)日：2016-09-20
申请号：US14494990
申请日：2014-09-24
发明人： Edward T. Maggio
IPC分类号： A61K38/08 , A61K47/26 , A61K9/00 , A61K9/127 , A61K9/19 , A61K31/70 , A61K45/06 , A61K47/10 , A61K47/18 , A61K47/36
CPC分类号： A61K38/12 , A61K9/0043 , A61K9/08 , A61K9/127 , A61K9/19 , A61K31/70 , A61K38/08 , A61K45/06 , A61K47/10 , A61K47/183 , A61K47/186 , A61K47/26 , A61K47/36
摘要： The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example octreotide or variant thereof.
摘要翻译： 本发明涉及含有烷基糖苷的组合物和增加其多肽，多肽或其变体（例如奥曲肽或其变体）的稳定性，降低聚集和免疫原性，增加生物学活性以及降低或预防纤维状形成的方法。
-
公开(公告)号：US11744895B2
公开(公告)日：2023-09-05
申请号：US17396044
申请日：2021-08-06
IPC分类号： A61K47/26 , A61K31/7016 , A61K31/485 , A61K9/00
CPC分类号： A61K47/26 , A61K31/485 , A61K31/7016 , A61K9/006 , A61K9/0043 , A61K9/0048 , A61K9/0056
摘要： Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
-
公开(公告)号：US20190209689A1
公开(公告)日：2019-07-11
申请号：US16352525
申请日：2019-03-13
发明人： Edward T. Maggio
IPC分类号： A61K47/26 , A61K31/4439 , A61K31/138 , A61K31/70 , A61K9/00 , A61K31/137 , A61K9/20
CPC分类号： A61K47/26 , A61K9/0043 , A61K9/0048 , A61K9/0056 , A61K9/006 , A61K9/2018 , A61K9/2095 , A61K31/137 , A61K31/138 , A61K31/4439 , A61K31/70
摘要： The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.046 秒)
